Breast Cancer Research and Treatment. 82(1):11-16, NOV 2003
PMID: 14672398
Issn Print: 0167-6806
Publication Date: 2003/11/01
E2F1 expression is related with the poor survival of lymph node-positive breast cancer patients treated with fluorouracil, doxorubicin and cyclophosphamide*
Sehwan Han;Kyeongmee Park;Byung-Noe Bae;Ki Kim;Hong-Joo Kim;Young-Duck Kim;Hong-Yong Kim;
+ Author Information
1Department of Surgery, 2Department of Pathology, Inje University Sanggye Paik Hospital, Seoul, South Korea
Abstract
The expressions of E2F1 and retinoblastoma protein (pRB) were analyzed in 165 lymph node-positive breast cancers. All patients underwent adjuvant chemotherapy with fluorouracil, doxorubicin and cyclophosphamide (FAC). E2F1 was expressed in 43.6% and pRB was expressed in 46.1%. E2F1 expression was significantly increased in pRB-expressing tumors and was associated with an S-phase fraction. By univariate survival analyses, E2F1 expression and ER were identified as significant prognostic factors for disease recurrence and patient survival. E2F1 was the only significant prognostic factor of patient outcome after FAC chemotherapy by multivariate analysis.
